Sustained viral suppression with dolutegravir monotherapy during 9,899 patient weeks of follow-up in individuals starting combination antiretroviral therapy during primary HIV infection (EARLY SIMPLIFIED): a randomized, controlled, multi-site, non-inferiority trial